SCHEMBL3492945

SCHEMBL3492945

O=C(O)c1ccc2ncoc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.54
TAS1R1 Q7RTX1 1/20 0.54
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NAMPT P43490 1/20 0.52
CTNNB1 P35222 3/20 0.49
WNT3A P56704 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
GAA P10253 5/20 0.46
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
MAPT P10636 3/20 0.46
POLB P06746 2/20 0.46
NSD2 O96028 1/20 0.46
THRB P10828 1/20 0.46
PABPC1 P11940 1/20 0.46
TNNI3 P19429 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL20898199 0.98 TAS1R3 (0.52) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL20897520 0.91 TAS1R3 (0.47) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
Pyrrolidine SCHEMBL22442341 0.88 TAS1R3 (0.45) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
SCHEMBL703854 0.85 CTNNB1 (0.65) NPC1RAB9ASMN1; SMN2NAMPTCTNNB1
SCHEMBL21129477 0.84 TAS1R3 (0.56) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
SCHEMBL5783191 0.84 TAS1R3 (0.52) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
SCHEMBL9298986 0.83 CTNNB1 (0.52) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
SCHEMBL29948972 0.83 RAB9A (0.55) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
SCHEMBL12173891 0.80 TAS1R3 (0.59) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2
SCHEMBL11989349 0.80 TAS1R3 (0.59) TAS1R3TAS1R1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118834382-A Preparation method of intrinsic antibacterial nylon based on end capping strategy 湘潭大学 2024-10-25 CN claimed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
CN-117050300-A Polylysine-based polymer adjuvant material, and preparation method and application thereof 中国科学院长春应用化学研究所 2023-11-14 CN claimed
US-20230255906-A1 Targeting Serpin B9 in Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-08-17 US claimed
CN-113603886-A Polyethyleneimine derivative and preparation method and application thereof 中国科学院长春应用化学研究所 2021-11-05 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4077287-B1 EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES PFIZER IRELAND PHARMACEUTICALS UNLIMITED COMPANY (IE) 2025-11-19 EP disclosed
EP-4077287-C0 EFFICIENT PROCESS FOR MAKING 6-CARBOXY BENZOXAZOLE DERIVATIVES PFIZER IRELAND PHARMACEUTICALS UNLIMITED COMPANY (IE) 2025-11-19 EP disclosed
WO-2025122558-A1 PYRAZINAMIDE-MIMICKING SMALL MOLECULES AS TREATMENT FOR TUBERCULOSIS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2025-06-12 WO disclosed
CN-115135639-B Efficient process for preparing 6-carboxybenzoxazole derivatives 辉瑞爱尔兰制药公司 2025-04-01 CN disclosed
US-5747492-A IMPROVING MEMORY; A-AMINO-3-HYDROXY-5-METHYL ISOOXAZOLE-4-PROPIONIC ACID THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-05-05 US disclosed
EP-0834311-A1 Method for inhibiting the growth of mammalian cells ROHM AND HAAS COMPANY (US) 1998-04-08 EP disclosed
EP-0816348-A1 Heterocyclic n-acetonylbenzamides and their use as fungicides ROHM AND HAAS COMPANY (US) 1998-01-07 EP disclosed
EP-0591786-B1 Photosensitive composition FUJI PHOTO FILM CO LTD (JP) 1996-05-15 EP disclosed
EP-0651746-A1 DRUGS THAT ENHANCE SYNAPTIC RESPONSES MEDIATED BY AMPA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-05-10 EP disclosed
CN-1094400-A Heterogeneous ring compound ZENECA LTD (GB) 1994-11-02 CN disclosed
EP-0591786-A2 Photosensitive composition FUJI PHOTO FILM CO., LTD. (JP) 1994-04-13 EP disclosed
WO-1994002475-A1 DRUGS THAT ENHANCE SYNAPTIC RESPONSES MEDIATED BY AMPA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH TAS1R3 1128/4885TAS1R1 1596/4885NPC1 212/4885
US-20230255906-A1 Targeting Serpin B9 in Cancer SERPINB10, SERPINB8, SERPINE1 TAS1R3 3520/4885TAS1R1 3465/4885NPC1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.